About: Coronavirus Disease 2019 (COVID‐19) in autoimmune hepatitis: a lesson from immunosuppressed patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Coronavirus Disease 2019 (COVID‐19) in autoimmune hepatitis: a lesson from immunosuppressed patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Coronavirus Disease 2019 (COVID‐19) in autoimmune hepatitis: a lesson from immunosuppressed patients
Creator	Invernizzi, Pietro Fagiuoli, Stefano Carbone, Marco Pasulo, Luisa Rigamonti, Cristina Cazzagon, Nora Claar, Ernesto Cristoferi, Laura Elia, Chiara Floreani, Annarosa Gerussi, Alessio Pozzi, Roberta Pozzoni, Pietro
Source	Medline; PMC
abstract	BACKGROUND & AIMS: Chronic immunosuppression is associated with increased and more severe viral infections. However, little is known about the association between immunosuppression and severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. Our aim was to describe the clinical course of immunosuppressed autoimmune hepatitis (AIH) patients during coronavirus disease 2019 (COVID‐19) infection in Italy. METHODS: Our study is a case series of AIH patients treated with immunosuppression, who tested positive for SARS‐CoV‐2 in March 2020 during outbreak of COVID‐19. RESULTS: Ten patients from six different hospitals in Italy were diagnosed with COVID‐19 during the outbreak of SARS‐CoV‐2 in March 2020. Seven subjects were female (70%) and age ranged from 27 to 73 years. Before the onset of SARS‐CoV‐2 infection, all patients were taking immunosuppressive therapy for AIH, and eight of them were on biochemical remission. Two other patients had recent acute onset of their AIH, and were consequently started high‐dose steroids, as per induction protocol. All patients had a respiratory syndrome and had a positive nasal swab for SARS‐CoV‐2. Five patients developed a CT‐confirmed COVID‐19 pneumonia. Six subjects received a combination of antiretroviral and antimalarial drugs. In seven patients the dosage of immunosuppressive medication was changed. Liver enzymes were repeated during SARS‐CoV‐2 infection in all hospitalized cases; they remained within the normal range in all cases, and improved in the two acute cases treated with high‐dose steroids. The clinical outcome was comparable to the reported cases occurring in non‐immunosuppressed subjects. CONCLUSION: Patients under immunosuppressive therapy for AIH developing COVID‐19 show a disease course presumptively similar to that reported in non‐immunosuppressed population. These data might help medical decision when dealing with SARS‐CoV‐2 infection in immunocompromised patients.
has issue date	2020-06-09(xsd:dateTime)
bibo:doi	10.1002/hep4.1557
bibo:pmid	32838102
has license	no-cc
sha1sum (hex)	3cfcd988d249afe71d5b1cb4361cf9d5b96f04d6
schema:url	https://doi.org/10.1002/hep4.1557
resource representing a document's title	Coronavirus Disease 2019 (COVID‐19) in autoimmune hepatitis: a lesson from immunosuppressed patients
has PubMed Central identifier	PMC7300554
has PubMed identifier	32838102
schema:publication	Hepatol Commun
resource representing a document's body	covid:3cfcd988d249afe71d5b1cb4361cf9d5b96f04d6#body_text
is schema:about of	named entity 'INFECTION' named entity 'ASSOCIATED WITH' named entity 'immunosuppressed' named entity 'Our' named entity 'autoimmune hepatitis' named entity 'Azathioprine' named entity 'immunosuppressive therapy' named entity 'COVID' named entity 'relapse' named entity 'infection' named entity 'antimalarial medication' named entity 'symptom' named entity 'viral infections' named entity 'COVID-19 disease' named entity 'pre-emptive strategies' named entity 'informed consent' named entity 'high-dose' named entity 'cough' named entity 'IL-6' named entity 'follow-up' named entity 'immunosuppression' named entity 'COVID' named entity 'SARS-CoV-2 pandemic' named entity 'immunosuppressive' named entity 'immunosuppressive drugs' named entity 'AIH' named entity 'remission' named entity 'network medicine' named entity 'control group' named entity 'SARS-CoV-2' named entity 'immunosuppressant' named entity 'steroids' named entity 'steroids' named entity 'infection' named entity 'relapse' named entity 'COVID' named entity 'severe acute respiratory syndrome' named entity 'Italy' named entity 'Azathioprine' named entity 'COVID' named entity 'drug withdrawal' named entity 'mechanism of action' named entity 'COVID-19' named entity 'headache' named entity 'March 2020' named entity 'AIH' named entity 'autoimmune condition' named entity 'COVID-19' named entity 'mercaptopurine' named entity 'SARS-CoV-2' named entity 'Middle East respiratory syndrome' named entity 'Italian' named entity 'liver function tests' named entity 'steroids' named entity 'biochemical' named entity 'immunosuppression' named entity 'prednisone' named entity 'Coronaviruses' named entity 'nasal swab' named entity 'Prednisone' named entity '6-mercaptopurine' named entity 'decompensated cirrhosis' named entity 'immunosuppression' named entity 'AIH' named entity 'COVID' named entity 'pneumonia' named entity 'COVID' named entity 'steroids' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software